TransMedics reports Q1 EPS 35c, consensus (5c)

Reports Q1 revenue $96.9M, consensus $83.78M. “We are pleased with our first quarter results as we simultaneously drove continued revenue growth, expanded our infrastructure, and achieved profitability,” said Waleed Hassanein, MD, President and Chief Executive Officer. “2024 represents another catalyst heavy year for TransMedics, and we are focused on executing across the board to drive further growth for our business and the overall transplant volumes to help patients in need for organ transplants.”